Bo Abrahamsen1, Pia Eiken, Richard Eastell. 1. Odense Patient Data Exploratory Network, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. b.abrahamsen@physician.dk
Abstract
CONTEXT: Bisphosphonates are the mainstay of anti-osteoporotic treatment and are commonly used for a longer duration than in the placebo-controlled trials. A link to development of atypical subtrochanteric or diaphyseal fragility fractures of the femur has been proposed, and these fractures are currently the subject of a U.S. Food and Drug Administration review. OBJECTIVE: Our objective was to examine the risk of subtrochanteric/diaphyseal femur fractures in long term users of alendronate. DESIGN: We conducted an age- and gender-matched cohort study using national healthcare data. PATIENTS: Patients were alendronate users, without previous hip fracture, who began treatment between January 1, 1996, and December 31, 2005 (n=39,567) and untreated controls, (n=158,268). MAIN OUTCOME MEASURES: Subtrochanteric or diaphyseal femur fractures were evaluated. RESULTS: Subtrochanteric and diaphyseal fractures occurred at a rate of 13 per 10,000 patient-years in untreated women and 31 per 10,000 patient-years in women receiving alendronate [adjusted hazard ratio (HR)=1.88; 95% confidence interval (CI)=1.62-2.17]. Rates for men were six and 31 per 10,000 patient-years, respectively (HR=3.98; 95% CI=2.62-6.05). The HR for hip fracture was 1.37 (95% CI=1.30-1.46)) in women and 2.47 (95% CI=2.07-2.95) in men. Risks of subtrochanteric/diaphyseal fracture were similar in patients who had received 9 yr of treatment (highest quartile) and patients who had stopped therapy after the equivalent of 3 months of treatment (lowest quartile). CONCLUSIONS: Alendronate-treated patients are at higher risk of hip and subtrochanteric/diaphyseal fracture than matched control subjects. However, large cumulative doses of alendronate were not associated with a greater absolute risk of subtrochanteric/diaphyseal fractures than small cumulative doses, suggesting that these fractures could be due to osteoporosis rather than to alendronate.
CONTEXT: Bisphosphonates are the mainstay of anti-osteoporotic treatment and are commonly used for a longer duration than in the placebo-controlled trials. A link to development of atypical subtrochanteric or diaphyseal fragility fractures of the femur has been proposed, and these fractures are currently the subject of a U.S. Food and Drug Administration review. OBJECTIVE: Our objective was to examine the risk of subtrochanteric/diaphyseal femur fractures in long term users of alendronate. DESIGN: We conducted an age- and gender-matched cohort study using national healthcare data. PATIENTS: Patients were alendronate users, without previous hip fracture, who began treatment between January 1, 1996, and December 31, 2005 (n=39,567) and untreated controls, (n=158,268). MAIN OUTCOME MEASURES: Subtrochanteric or diaphyseal femur fractures were evaluated. RESULTS: Subtrochanteric and diaphyseal fractures occurred at a rate of 13 per 10,000 patient-years in untreated women and 31 per 10,000 patient-years in women receiving alendronate [adjusted hazard ratio (HR)=1.88; 95% confidence interval (CI)=1.62-2.17]. Rates for men were six and 31 per 10,000 patient-years, respectively (HR=3.98; 95% CI=2.62-6.05). The HR for hip fracture was 1.37 (95% CI=1.30-1.46)) in women and 2.47 (95% CI=2.07-2.95) in men. Risks of subtrochanteric/diaphyseal fracture were similar in patients who had received 9 yr of treatment (highest quartile) and patients who had stopped therapy after the equivalent of 3 months of treatment (lowest quartile). CONCLUSIONS:Alendronate-treated patients are at higher risk of hip and subtrochanteric/diaphyseal fracture than matched control subjects. However, large cumulative doses of alendronate were not associated with a greater absolute risk of subtrochanteric/diaphyseal fractures than small cumulative doses, suggesting that these fractures could be due to osteoporosis rather than to alendronate.
Authors: Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings Journal: JAMA Date: 2006-12-27 Impact factor: 56.272
Authors: D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud Journal: Lancet Date: 1996-12-07 Impact factor: 79.321
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Roland D Chapurlat; Monique Arlot; Brigitte Burt-Pichat; Pascale Chavassieux; Jean Paul Roux; Nathalie Portero-Muzy; Pierre D Delmas Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741
Authors: S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix Journal: JAMA Date: 1998 Dec 23-30 Impact factor: 56.272
Authors: Jan J Stepan; David B Burr; Imre Pavo; Adrien Sipos; Dana Michalska; Jiliang Li; Astrid Fahrleitner-Pammer; Helmut Petto; Michael Westmore; David Michalsky; Masahiko Sato; Harald Dobnig Journal: Bone Date: 2007-05-18 Impact factor: 4.398
Authors: Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich Journal: J Orthop Trauma Date: 2008 May-Jun Impact factor: 2.512
Authors: Crystal K Tjhia; Clarita V Odvina; D Sudhaker Rao; Susan M Stover; Xiang Wang; David P Fyhrie Journal: Bone Date: 2011-09-18 Impact factor: 4.398
Authors: Judith Haschka; Friederike Kühne; Christian Muschitz; Thomas Pirker; Roland Kocijan; Christina Bittighofer; Angela Trubrich; Heinrich Resch Journal: Wien Klin Wochenschr Date: 2011-08-15 Impact factor: 1.704